Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs

© 2022 by the Journal of Rheumatology This is an Open Access article, which permits use, distribution, and reproduction, without modification, provided the original article is correctly cited and is not used for commercial purposes.

Author Information

Majed M. Khraishi1 ⇑,
Valencia P. Remple2,
Samuel Silverberg3,
Jacqueline C. Stewart4,
Brandusa Florica5 and
Louis Bessette6

¹M.M. Khraishi, MB BCh, FRCP(C), Memorial University of Newfoundland, St. John’s, Newfoundland and Labrador, Canada;
²V.P. Remple, MSN, PhD, AbbVie Biopharmaceuticals Sarl, Rungis, France;
³S. Silverberg, MD, Etobicoke General Hospital, Toronto, Ontario, Canada;
⁴J.C. Stewart, MD, FRCPC, University of British Columbia, Penticton, British Columbia, Canada;
⁵B. Florica, MD, PhD, FRCPC, University of Toronto, Toronto, Ontario, Canada;
⁶L. Bessette, MD, FRCPC, MSc, Laval University, Centre Hospitalier de l’Université Laval, Quebec City, Quebec, Canada.